NS Pharma, Inc.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS7
PHASE 3 / 2-31
RECRUITING2
READOUTS ≤12 MONTHS2
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Viltolarsen NCT04768062 |
P3 | Active, not recruiting | Duchenne Muscular Dystrophy | 74 | 2025-10 |
| NS-229 NCT06046222 |
P2 | Active, not recruiting | Eosinophilic Granulomatosis With Polyangiitis; Churg-Strauss Syndrome | 45 | 2026-12 (+20 mo) |
| NS-089/NCNP-02 NCT05996003 |
P2 | Active, not recruiting | Duchenne Muscular Dystrophy; Exon 44 | 20 | 2027-02-26 (+21 mo) |
| NS-050/NCNP-03 NCT06053814 |
P1/2 | Active, not recruiting | Duchenne Muscular Dystrophy | 20 | 2028-03 (+21 mo) |
| NS-863 Low Dose NCT07441200 |
P2 | Recruiting | Pulmonary Arterial Hypertension | 135 | 2028-08-01 |
| NS-863 Low Dose NCT07441278 |
P2 | Recruiting | Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | 177 | 2028-09-14 |
| DMD NCT07943598 |
P2 | Enrolling by invitation | Duchenne Muscular Dystrophy; Exon 44 | 20 | 2029-09-03 |